Customs delayed a filing rule. Your medicine faces separate rules.

If you get medicine mailed from abroad, a rule set to start October 22 is now delayed to January 20. The delay gives the shipping system more time to prepare. It doesn’t change whether your medicine is allowed in.

On October 14, U.S. Customs and Border Protection moved the compliance date for certain electronic international-mail filings from October 22, 2026, to January 20, 2027. The agency says the extra 90 days gives importers, brokers and logistics providers time to prepare and avoid disruption.

The filing process is called Entry Type 13. It puts information about covered postal shipments into the government’s electronic import system. Its purpose is to change how those entries are processed, including shipments subject to specified import taxes or another agency’s authority.

The information travels ahead of the box

The extension delays mandatory use for the affected shipments. It does not abandon the planned requirement. For businesses handling mail, that means preparation continues against a later deadline rather than disappearing from the list of work to do.

Representatives Jan Schakowsky and Mark Pocan led a 71-member request calling for improved screening alongside continued access to genuine, non-controlled medicines for personal use. Their position is that addressing risky shipments should not create avoidable barriers for those patients.

Prescription Justice, an organization that supports personal importation, also reported a separate Republican letter. Its account is relevant as an interested group’s description of the debate. It is not an independent measurement of patient costs or delivery outcomes.

A filing rule cannot authorize the contents

The Food and Drug Administration has a separate role in the legality of medicine imports. It says personal importation of medicines not approved for U.S. sale is generally not permitted, while describing circumstances in which it may exercise enforcement discretion.

Enforcement discretion means the agency may handle a case under its guidance. It does not create a general right to import any product someone orders. Controlled substances have further restrictions.

What the extra time needs to produce

The reviewed records establish neither a permanent personal-prescription exemption nor a typical extra patient cost.

CBP also described a separate October 8 proposal that would broaden requirements. A proposal is an action under consideration; the announced date extension is a completed change to the implementation calendar. They should be tracked as different developments.